Infant Respiratory Syncytial Virus Immunization Through Maternal Vaccination and Nirsevimab

What factors were associated with receipt of respiratory syncytial virus (RSV) immunization by maternal RSV vaccine or nirsevimab in infants during the 2023-2024 and 2024-2025 RSV seasons?In this cohort study of 13 195 infants who were seen for medical care before 8 months of age, 58% of 6245 infants and 75% of 6950 infants received maternal RSV vaccine or nirsevimab in the 2023-2024 and 2024-2025 RSV seasons, respectively. Infants with public insurance had lower odds of receiving either type of RSV immunization.These findings suggest that despite improved RSV immunization, socioeconomic differences affected receipt of RSV immunization in infants.

Corresponding Author: Karen P. Acker, MD, 505 E 70th St, NY, NY 10021 (kpa9002@med.cornell.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.